TOP > Information Kit > History
- History(P14)
| Sankyo Co., Ltd. | Year | Daiichi Pharmaceutical Co., Ltd. | ||
|---|---|---|---|---|
 |
・Founding of Sankyo Shoten jointly financed by Matasaku Shiobara (photo), Shotaro Nishimura and Genjiro Fukui ・Launched digestive enzyme Taka-Diastase® based on a discovery by Dr. Jokichi Takamine |
1899 Meiji 32 |
- | |
 |
・Dr. Umetaro Suzuki discovered vitamin B1 (Orizanin®) from rice bran, establishing the basis for the theory of vitamins | 1910 Meiji 43 |
- | |
 |
・Established Sankyo Co., Ltd. ・Dr. Jokichi Takamine became the first president |
1913 Taisho 2 |
- | |
| - | 1915 Taisho 4 |
 |
・Founding of Arsemin Shokai by Dr. Katsuzaemon Keimatsu and others | |
| - | 1918 Taisho 7 |
 |
・Established Daiichi Pharmaceutical Co., Ltd. ・Seinosuke Shibata appointed as first president |
|
| - | 1921 Taisho 10 |
 |
・Launched Bosmin®, a vasoconstriction/hemostasis and asthma medicine | |
| - | 1937 Showa 12 |
 |
・Launched Therapol®, the first domestically produced Sulfa | |
| ・Listed on Tokyo Stock Exchange | 1949 Showa 24 |
- | ||
 |
・Launched Lulu® (OTC medicine), cold medicine (photo) ・Manufactured the first domestically produced antibiotic preparation Chloromycetin® |
1951 Showa 26 |
- | |
| ・Established a representative office in New York | 1961 Showa 36 |
- | ||
| - | 1962 Showa 37 |
 |
・Launched the world's first anti-plasmin medicine Ipsilon® | |
| ・Established a representative office in Basel, Switzerland | 1963 Showa 38 |
- | ||
| - | 1966 Showa 41 |
 |
・Launched Patecs®, the first shape-forming poultice (OTC medicine) | |
| - | 1980 Showa 55 |
・Established a representative office in New York | ||
 |
・Launched Captoril®, the world's first renin-angiotensin-type antihypertensive agent | 1983 Showa 58 |
- | |
| ・Established Sankyo USA Corporation (New York, U.S.A.) ・Established Sankyo Europa GmbH (Dusseldorf, West Germany) |
1985 Showa 60 |
- | ||
 |
・Launched Mevalotin®, an HMG-CoA reductase inhibitor (antihyperlipidemic agent) | 1989 Start of Heisei |
- | |
| ・Acquired the Luitpold Werke group in Munich, Germany | 1990 Heisei 2 |
・Established Korea Daiichi Pharmaceutical Co., Ltd. | ||
| - | 1993 Heisei 5 |
 |
・Launched Cravit®, a broad-spectrum oral antibacterial agent ・Established Daiichi Pharmaceutical UK Ltd. |
|
| - | 1998 Heisei 10 |
・Established Daiichi Pharmaceutical (Beijing) Co. Ltd. in China | ||
 |
・Launched antihypertensive agent Olmesartan medoxomil in the U.S. and Germany (marketed as Benicar® and Olmetec®, respectively) as a strategic global product | 2002 Heisei 14 |
- | |
| Year | Daiichi Sankyo Company, Limited | |||
|---|---|---|---|---|
| 2005 Heisei 17 |
 |
Establishment of Daiichi Sankyo Company, Limited as a joint holding company | ||
| 2006 Heisei 18 |
 |
・Started operations of Daiichi Sankyo Healthcare Co., Ltd. ・Started operations of Daiichi Sankyo, Inc., the new U.S. organization ・Started operations of Daiichi Sankyo Europe GmbH, the new European organization |
||
| 2007 Heisei 19 |
|
Started operations as the newly formed Daiichi Sankyo Company, Limited | ||
Daiichi + Sankyo Synergies
In April 2007, Daiichi Sankyo started operations as a single organization. By combining the unique strengths of the former Daiichi and Sankyo, we are realizing synergies as a leader in our fields of expertise based on the philosophy of “first-in-class, best-in-class.” This integration strengthens the R&D infrastructure needed to maintain a steady flow of new products by combining the creative energies of our researchers and enabling more efficient R&D investments in fields of specialization. The integration also bolsters our domestic and overseas sales forces and distribution networks.
